PetMed Express

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PetMed Express reports Q1 2023 earnings, anticipates growth from PetCareRx acquisition

PetMed Express faced sales decline, but the acquisition of PetCareRx and strong new customer growth provide optimism for future profitability. Financial stability, operational focus, and strategic partnerships position the company for long-term success.

PetMed Express reports Q3 sales dip but gains new customers

PetMed Express navigated challenges with a 3% decrease in YoY sales but gained 9% more net new customers. The company's focus on pet health expertise and expanding offerings positions it for future growth.
Despite advertising spending increases, PetMed maintains a strong balance sheet with over $102 million in unrestricted cash. Management's confidence in future prospects and innovative strategies bode well for the company's growth trajectory.

PetMed Express reports sales decline, eyes growth from acquisitions

PetMed Express focused on pet wellness, recent acquisitions, and strategic investments in telemedicine and pet insurance.
Despite sales decline in fiscal year 2023, the company aims for growth from the PetCareRx acquisition in 2024.
Challenges in over-the-counter medication sales and a net loss in Q4 were offset by a strong cash position and strategic focus on growth.

PetMed Express reports record revenue growth and expands pet insurance

PetMed Express (PETS) demonstrated strong financial performance in Q1 2024, with record-setting revenue growth and a focus on sustainable long-term growth.
The company's strategic initiatives, including the integration of the PetCareRx acquisition and expansion into the pet insurance market, position it for future success.
While facing challenges in a competitive market, PetMed Express has opportunities to solidify its market leadership in pet wellness and healthcare through customer-centric strategies.

PetMed Express reports Q2 growth, shifts focus to tech investments

PetMed Express (PETS) demonstrated solid financial performance in Q2 2024 with revenue growth and operational enhancements. While facing challenges in customer retention and market conditions, the company is strategically investing in technology and growth initiatives. With a focus on long-term sustainability and innovation, PetMed Express aims to drive growth and shareholder value in the pet health sector.

PetMed Express reports strong sales growth amidst accounting challenges

PetMed Express shows resilience in sales growth despite accounting challenges.
The company's focus on transparency and customer programs is a key strength.
Challenges include the need for a financial restatement and maintaining investor confidence.
Opportunities lie in strengthening internal controls and driving growth through acquisitions.

PetMed Express reports sales growth, invests in tech for future

PetMed Express (PETS) reported positive sales growth in Q4 2024 driven by the PetCareRx acquisition, despite a net loss due to acquisition-related expenses.
The company's customer-centric focus, strategic investments in technology, and strong leadership team additions position it well for future growth.
Challenges include managing expenses post-acquisition and navigating competitive pressures in the pet medications market, while opportunities exist in market expansion and operational enhancements.

PetMed Express (PETS) reports Q1 challenges but sees early improvements

PetMed Express (PETS) navigated a transition quarter with a focus on growth and profitability. Despite a sales decline and margin decrease, early signs of improvement were observed. The company emphasized optimizing cost structure, enhancing customer growth strategies, and implementing technology improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PetMed Express, Inc. provides markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, and generic substitutes. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Boeing

Cisco Systems

Nikola

Oracle

Seres Therapeutics

Niu Technologies - ADR

Quantum Corporation

With the trading day about halfway over, the broad markets pushed lower after a decent start to the day.

Boeing, Cisco, Nikola, Oracle and More Friday Afternoon Analyst Calls

Chewy

Freshpet

IDEXX Laboratories

PetIQ

Trupanion

Zomedica

Pet stocks have performed very well recently, and many analysts believe that this trend will continue as the industry grows. The post 7 Pet Stocks for Animal Lovers and Investors Alike appeared first on InvestorPlace.

7 Pet Stocks for Animal Lovers and Investors Alike

BigCommerce Holdings, Inc.

FuboTV

Tilray Brands

ViacomCBS

Watch out if this trend starts to lose steam, but these five short-squeeze stocks could continue to surge higher in 2021. The post 5 Short-Squeeze Stocks with Big Upside appeared first on InvestorPlace.

5 Short-Squeeze Stocks with Big Upside

Revlon

Express

Why Express, Revlon, and PetMed Express Were Soaring Today

PetMed Express has the only attractive yield in the pet stock universe and has no debt. It has lagged other pet stocks and looks undervalued

Puttin' On The Dog: PetMed Express And 9 Other Pet Stocks

Shares of online pet pharmacy retailer PetMed Express Inc. (NASDAQ:PETS) plunged more than 12% on Tuesday following the release of its third-quarter results. The Delray Beach, Florida-based company announced its earnings for the period ended Dec. 31 missed Wall Street's expectations.

PetMed Fails to Woo Investors After Earnings Miss

Shares of the online pet pharmacy pulled back after it reported earnings this morning.

Why PetMed Express Stock Was Falling Today

PetMed Express, Inc. (PETS) CEO Mendo Akdag on Q3 2020 Results - Earnings Call Transcript

PetMed Express Inc. stock slumped 8.6% in Tuesday premarket trading before rebounding to a 2.1% decline after the pet pharmacy reported fiscal third-quarter profit that missed expectations. Net income totaled $7.6 million, or 38 cents per share, up from $6.8 million, or 34 cents per share, last year.

PetMed Express stock slumps after profit miss

Nestle SA

Zoetis

Rising pet ownership rates and a steadily increasing average household spending provide a powerful tailwind to this investment theme. Pet food, animal health, veterinary equipment, and specialized e-commerce are all fields prone to profit from the secular growth trend.

Growth In Pet Spending Is Off The Leash, Here Is How To Profit From It

Church & Dwight

Lemonade

Americans love their pets, and no pandemic, not even the novel coronavirus, will change that, bolstering these eight pet stocks. The post 8 Pet Stocks That Will Make You Purr appeared first on InvestorPlace.

8 Pet Stocks That Will Make You Purr

ANI Pharma

Surgalign Holdings, Inc.

Vanda Pharmaceuticals

Surmodics

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

5 Medical Technology Stocks Popular Among Gurus

Prescription sales are driving profitability. Orders showing YoY growth for three Quarters.

PetMed Express: Mea Culpa, Buy As They Are Gaining Traction In Prescriptions

PetsMed Express reported its fiscal Q2 earnings highlighted by firming margins and higher earnings. The stock has been volatile in recent months considering more subdued expectations compared to a stronger first half of the year which was boosted by the pandemic.

PetsMed: Attractive 3.7% Dividend Yield Supported By Solid Fundamentals

PetMed Express (PETS) on Q2 2020 Results - Earnings Call Transcript

Shares of PetMed Express (NASDAQ:PETS) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 27.27% over the past year to $0.42, which beat the estimate of $0.40.

Recap: PetMed Express Q2 Earnings

Diluted EPS $0.42 vs $0.33 per share   Quarterly Reorder Sales Increased 9.6% Gross Margins Improved Sequentially from 27.8% to 30.5%

PetMed Express d/b/a 1-800-PetMeds Announces Its Second Fiscal Quarter Financial Results and Its Quarterly Dividend of $0.28 per Share

DELRAY BEACH, Fla., Oct. 19, 2020 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter ended September 30, 2020 on Monday, October 26, 2020 at 8:00 A.M. Eastern Time, then at 8:30 A.M. Eastern Time, Menderes Akdag, the Company's Chief Executive Officer and President, will host a conference call to review the financial results.

PetMed Express D/B/A 1-800-PetMeds To Announce Its Second Quarter Financial Results On October 26, 2020

Chevron

Ford Motor Company

Federal Realty Investment Trust

AT&T

Exxon Mobil

Some dividend stocks have high yields, but aren't dependable. Some are safe but low yielding.

7 Dividend Stocks To Buy For Adventurous Investors 

Covetrus Inc

J. M. Smucker

Chewy, Zoetis and FreshPet are just a couple of the names on our list of pet stocks to buy. Let's look at this growing industry more closely.

7 Pet Stocks to Adopt Today 

B&G Foods

Calavo Growers

Macerich

Smith & Wesson Brands

Small-cap stocks that pay dividends can offer huge opportunities to investors. Find out which stocks have growth potential and relative stability.

The 5 Best Small-Cap Stocks for Dividends

These four pet stocks should benefit from both increased ownership and higher spending as the "humanization" of pets continues. The post 4 Pet Stocks Catering to Stay-at-Home Trends appeared first on InvestorPlace.

4 Pet Stocks Catering to Stay-at-Home Trends

Merck

VanEck Vectors Pharmaceutical ETF

These trio of pets stocks to buy offers global potential for investors looking to play the growing trend of owning a furry friend.
The post 3 Pet Stocks to Buy for Your Furry Friend appeared first on InvestorPlace.

3 Pet Stocks to Buy for Your Furry Friend

It's raining cats and dogs these days. Investors may want to bring their buckets.

3 Hot Pet Stocks to Buy in August

PETS has come within one standard deviation of its 160-week moving average, a historically bullish trendline that could signal more upside for the stock.

News for PetMed Express Stock (PETS)